· Published by Health Canada · Official notice
This is duplicated text of a letter from Bristol-Myers Squibb.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
Bristol-Myers Squibb
Group pharmaceutique
Pharmaceutical Group
2365, Côte-de-Liesse, Saint-Laurent (Québec) H4N 2M7
514 333-3200 Fax 514 335-4102
March 6, 2002
Subject: Symptoms Mimicking The Clinical Presentation of Guillain-Barré Syndrome Associated with ZERIT® (stavudine, d4T)
Dear Healthcare Professional:
Bristol-Myers Squibb Canada Inc. is alerting you to emerging safety information regarding ZERIT® (stavudine, d4T). The following information will be incorporated into the Product Monograph:
Reports have been received of rare occurrences of rapidly ascending neuromuscular weakness, mimicking the clinical presentation of Guillain-Barré syndrome (including respiratory failure), in HIV-infected patients receiving stavudine in combination with other antiretrovirals. There were a total of 22 reports out of an estimated 832,383 patient years of experience with ZERIT® (stavudine, d4T) since 1994. Seven cases were fatal. No known Canadian cases have been reported. Most of the cases were reported in the setting of lactic acidosis or symptomatic hyperlactatemia and, in most, antiretroviral therapy had been continued in the presence of nonspecific signs compatible with early symptomatic hyperlactatemia that preceded the development of neuromuscular signs and symptoms. If motor weakness develops in a patient receiving stavudine, the drug should be discontinued.
Bristol-Myers Squibb Canada Inc. would like to remind healthcare providers caring for persons with HIV of the potential for lactic acidosis as a complication of therapy with nucleoside analogues, including ZERIT® (stavudine, d4T). The early signs and symptoms of clinical events associated with hyperlactatemia should receive careful attention because of the life-threatening potential of the most extreme manifestation, lactic acidosis syndrome (LAS).
Confirmed elevations of serum lactate may be associated with a broad spectrum of clinical manifestations, ranging from asymptomatic hyperlactatemia, through symptomatic non-acidotic hyperlactatemia (SHL), to acute severe LAS. Early signs and symptoms associated with a high lactate may be subtle and include generalized fatigue, digestive symptoms (nausea, vomiting, abdominal pain, and sudden unexplained weight loss), respiratory symptoms (tachypnea and dyspnea), or neurologic symptoms (including motor weakness). Patients with these symptoms should promptly interrupt antiretroviral therapy, and a full medical work-up should be performed rapidly.Footnote 1 Permanent discontinuation of stavudine should be considered for patients with confirmed LAS. It is important to note that symptoms associated with hyperlactatemia may continue or worsen following discontinuation of antiretroviral therapy.
At this time, prospective monitoring of lactate levels does not appear to be helpful in predicting the subsequent occurrence of SHL or LAS.Footnote 1
Although relative rates of lactic acidosis have not been assessed in prospective well-controlled trials, longitudinal cohort and retrospective studies suggest that this infrequent event may be more often associated with antiretroviral combinations containing stavudine.Footnote 2, Footnote 3, Footnote 4
Bristol-Myers Squibb continues to work actively with Health Canada to monitor adverse event reports and to ensure that up-to-date information regarding the use of ZERIT® is available.
Reporting rates determined on the basis of spontaneously reported post-marketing adverse events are generally presumed to underestimate the risks associated with drug treatments.
The Product Monograph for ZERIT® (stavudine, d4T) is currently being updated with this information. The revised Product Monograph will be available to Healthcare Professionals upon request. Current and future stavudine-treated patients should be fully informed of the above information.
Please regularly consult the official Product Monograph for complete prescribing information.
For additional information regarding the recommended use of stavudine and if you have any further questions, please contact the Medical Information Department at Bristol-Myers Squibb Canada Inc. at 1-800-267-1088 ext. 2078.
Sincerely,
original signed by
Nacia Faure, M.D.
Medical Director
Any suspected adverse reactions can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Bureau of Licensed Product Assessment
Therapeutic Products Directorate
Health Canada
Address Locator: 0201C2
Ottawa, Ontario, K1A 1B9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The ADR Reporting Form can be found in The Canadian Compendium of Pharmaceuticals and Specialties, or on the TPD website, along with the ADR Guidelines.
Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 2001; 15 ; 795-797.
John M, Moore CB, James IR et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717-723.
Lonergan JT, Havlir D, Barber E, Mathews WC. Incidence and Outcome of Hyperlactatemia Associated with Clinical Manifestations in HIV-Infected Adults Receiving NRTI-Containing Regimens. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 624].
Gerard Y, Maulin L et al. Symptomatic hyperlactatemia: an emerging complication of antiretroviral therapy. AIDS 2000; 14: 2723-2730.